$CDNA
CareDx, Inc. Stock $cdna

$cdna Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-K Financial Statement

#000121723420000033 Filed on February 28, 2020

Income Statement

Concept	2019 Q4	2019	2018 Q4
Revenue	$35.82M	$127.1M	$23.51M
YoY Change	52.37%	65.95%	88.03%
Cost Of Revenue	$12.72M	$45.46M	$10.51M
YoY Change	21.03%	37.8%	88.01%
Gross Profit	$23.11M	$81.61M	$13.00M
YoY Change	77.77%	87.26%	88.13%
Gross Profit Margin	64.52%	64.23%	55.3%
Selling, General & Admin	$19.70M	$75.43M	$11.63M
YoY Change	69.39%	68.96%	59.32%
% of Gross Profit	85.24%	92.43%	89.46%
Research & Development	$8.950M	$30.71M	$3.780M
YoY Change	136.77%	111.6%	24.75%
% of Gross Profit	38.73%	37.63%	29.08%
Depreciation & Amortization	$1.680M	$1.600M	$1.180M
YoY Change	42.37%	33.33%	15.69%
% of Gross Profit	7.27%	1.96%	9.08%
Operating Expenses	$28.65M	$151.6M	$15.41M
YoY Change	85.92%	64.52%	37.59%
Operating Profit	-$5.540M	-$24.53M	-$2.410M
YoY Change	129.88%	57.48%	-43.82%
Interest Expense	$640.0K	$985.0K	$1.390M
YoY Change	-53.96%	-126.61%	-104.98%
% of Operating Profit
Other Income/Expense, Net	-$80.00K	$585.0K	$2.710M
YoY Change	-102.95%	-101.79%	-1003.33%
Pretax Income	-$4.980M	-$23.95M	-$4.090M
YoY Change	21.76%	-50.33%	-87.42%
Income Tax	-$200.0K	-$1.979M	-$340.0K
% Of Pretax Income
Net Earnings	-$4.777M	-$21.97M	-$3.755M
YoY Change	27.22%	-53.02%	-88.14%
Net Earnings / Revenue	-13.34%	-17.29%	-15.97%
Basic Earnings Per Share	-$0.11	-$0.52	-$0.09
Diluted Earnings Per Share	-$0.11	-$0.52	-$0.09
COMMON SHARES
Basic Shares Outstanding	42.46M shares	42.15M shares	40.10M shares
Diluted Shares Outstanding	42.46M shares	42.15M shares	40.10M shares

Balance Sheet

Concept	2019 Q4	2019	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$38.20M	$38.20M	$64.60M
YoY Change	-40.87%	-40.87%	282.25%
Cash & Equivalents	$38.22M	$38.20M	$64.62M
Short-Term Investments
Other Short-Term Assets	$3.600M	$3.600M	$1.800M
YoY Change	100.0%	100.0%	28.57%
Inventory	$6.014M	$6.000M	$4.943M
Prepaid Expenses
Receivables	$24.06M	$24.10M	$9.760M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$71.92M	$71.90M	$81.11M
YoY Change	-11.33%	-11.34%	203.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.430M	$9.200M	$4.134M
YoY Change	7.16%	124.39%	99.23%
Goodwill	$23.86M		$12.01M
YoY Change	98.73%		0.0%
Intangibles	$45.54M		$33.25M
YoY Change	36.96%		0.34%
Long-Term Investments
YoY Change
Other Assets	$1.000M	$1.300M	$0.00
YoY Change		550.0%	-100.0%
Total Long-Term Assets	$79.81M	$79.80M	$49.58M
YoY Change	60.97%	60.89%	-12.7%
TOTAL ASSETS
Total Short-Term Assets	$71.92M	$71.90M	$81.11M
Total Long-Term Assets	$79.81M	$79.80M	$49.58M
Total Assets	$151.7M	$151.7M	$130.7M
YoY Change	16.1%	16.07%	56.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.506M	$5.500M	$4.711M
YoY Change	16.88%	17.02%	38.93%
Accrued Expenses	$18.80M	$18.80M	$11.20M
YoY Change	67.86%	67.86%	28.74%
Deferred Revenue	$3.686M		$39.00K
YoY Change	9351.28%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00		$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$34.83M	$34.80M	$19.50M
YoY Change	78.57%	78.46%	-54.54%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$1.751M	$15.90M	$2.294M
YoY Change	-23.67%	29.27%	74.45%
Total Long-Term Liabilities	$1.751M	$15.90M	$2.294M
YoY Change	-23.67%	29.27%	-88.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$34.83M	$34.80M	$19.50M
Total Long-Term Liabilities	$1.751M	$15.90M	$2.294M
Total Liabilities	$52.74M	$52.70M	$34.77M
YoY Change	51.68%	51.44%	-61.16%
SHAREHOLDERS EQUITY
Retained Earnings	-$333.8M		-$311.8M
YoY Change	7.04%		16.35%
Common Stock	$438.0M		$412.1M
YoY Change	6.3%		55.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$99.00M	$99.00M	$95.93M
YoY Change
Total Liabilities & Shareholders Equity	$151.7M	$151.7M	$130.7M
YoY Change	16.1%	16.07%	56.4%

Cashflow Statement

Concept	2019 Q4	2019	2018 Q4
OPERATING ACTIVITIES
Net Income	-$4.777M	-$21.97M	-$3.755M
YoY Change	27.22%	-53.02%	-88.14%
Depreciation, Depletion And Amortization	$1.680M	$1.600M	$1.180M
YoY Change	42.37%	33.33%	15.69%
Cash From Operating Activities	-$1.080M	-$2.769M	$2.000M
YoY Change	-154.0%	-30.9%	-193.02%
INVESTING ACTIVITIES
Capital Expenditures	-$1.230M	-$3.350M	-$960.0K
YoY Change	28.13%	-264.62%	966.67%
Acquisitions		$18.23M
YoY Change
Other Investing Activities	-$110.0K	-$19.23M	$0.00
YoY Change		2686.96%	-100.0%
Cash From Investing Activities	-$1.340M	-$22.58M	-$960.0K
YoY Change	39.58%	184.76%	-80.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	80.00K	-$132.0K	37.31M
YoY Change	-99.79%	-100.26%	108.2%
NET CHANGE
Cash From Operating Activities	-1.080M	-$2.769M	2.000M
Cash From Investing Activities	-1.340M	-$22.58M	-960.0K
Cash From Financing Activities	80.00K	-$132.0K	37.31M
Net Change In Cash	-2.340M	-$26.33M	38.35M
YoY Change	-106.1%	-168.68%	257.41%
FREE CASH FLOW
Cash From Operating Activities	-$1.080M	-$2.769M	$2.000M
Capital Expenditures	-$1.230M	-$3.350M	-$960.0K
Free Cash Flow	$150.0K	$581.0K	$2.960M
YoY Change	-94.93%	-109.62%	-243.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019	dei	Document Type DocumentType	10-K
CY2019	dei	Amendment Flag AmendmentFlag	false
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-12-31
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019	dei	Entity Registrant Name EntityRegistrantName	CareDx, Inc.
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001217234
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019	dei	Entity Small Business EntitySmallBusiness	false
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	42879426	shares
CY2019Q2	dei	Entity Public Float EntityPublicFloat	1502000000	USD
CY2019	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2019	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38223000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	64616000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	24057000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9760000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	6014000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	4943000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3628000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1795000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	71922000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	81114000	USD
CY2019Q4	cdna	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	4430000	USD
CY2018Q4	cdna	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	4134000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4730000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	45541000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	33252000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	23857000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	12005000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	256000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	192000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1000000	USD
CY2019Q4	us-gaap	Assets Assets	151736000	USD
CY2018Q4	us-gaap	Assets Assets	130697000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5506000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4711000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	12484000	USD
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9156000	USD
CY2019Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	16838000	USD
CY2018Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	5637000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	34828000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19504000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1973000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2968000	USD
CY2019Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	6607000	USD
CY2018Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	10003000	USD
CY2019Q4	cdna	Deferred Payments For Intangible Assets Noncurrent DeferredPaymentsForIntangibleAssetsNoncurrent	5207000	USD
CY2018Q4	cdna	Deferred Payments For Intangible Assets Noncurrent DeferredPaymentsForIntangibleAssetsNoncurrent	0	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4121000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2294000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	52736000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	34769000	USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42498430	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42498430	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41384960	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41384960	shares
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	42000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	41000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	437976000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	412010000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5205000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4278000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-333813000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-311845000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	99000000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	95928000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	151736000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	130697000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	127068000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	76569000	USD
CY2017	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48324000	USD
CY2019	us-gaap	Cost Of Revenue CostOfRevenue	45455000	USD
CY2018	us-gaap	Cost Of Revenue CostOfRevenue	32987000	USD
CY2017	us-gaap	Cost Of Revenue CostOfRevenue	21371000	USD
CY2019	us-gaap	Gross Profit GrossProfit	81613000	USD
CY2018	us-gaap	Gross Profit GrossProfit	43582000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30711000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14514000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12388000	USD
CY2017	us-gaap	Gross Profit GrossProfit	26953000	USD
CY2019	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	38894000	USD
CY2018	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	21670000	USD
CY2017	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	12808000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	36540000	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22976000	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20093000	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2017	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	1958000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	106145000	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	59160000	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	47247000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-24532000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-15578000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-20294000	USD
CY2019	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	985000	USD
CY2018	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-3701000	USD
CY2017	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-5863000	USD
CY2019	cdna	Extinguishment Of Debt And Conversion Of Debt To Equity Expenses ExtinguishmentOfDebtAndConversionOfDebtToEquityExpenses	0	USD
CY2018	cdna	Extinguishment Of Debt And Conversion Of Debt To Equity Expenses ExtinguishmentOfDebtAndConversionOfDebtToEquityExpenses	5780000	USD
CY2017	cdna	Extinguishment Of Debt And Conversion Of Debt To Equity Expenses ExtinguishmentOfDebtAndConversionOfDebtToEquityExpenses	459000	USD
CY2019	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	319000	USD
CY2018	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-22978000	USD
CY2017	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-29622000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-719000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-178000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1031000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	585000	USD
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-32637000	USD
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-36975000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23947000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-48215000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-57269000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1979000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1434000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1709000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-21968000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	-46781000	USD
CY2017	us-gaap	Profit Loss ProfitLoss	-55560000	USD
CY2019	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2018	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-25000	USD
CY2017	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-91000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-21968000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-46756000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-55469000	USD
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.52
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.31
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.52
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.31
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.38
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.38
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42151617	shares
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35638956	shares
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23332503	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42151617	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35638956	shares
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23332503	shares
CY2019	us-gaap	Profit Loss ProfitLoss	-21968000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	-46781000	USD
CY2017	us-gaap	Profit Loss ProfitLoss	-55560000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-927000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-48714000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-54254000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1933000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1306000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-22895000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-25000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-99000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22895000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-48689000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-54155000	USD
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	19761000	USD
CY2017	cdna	Issuance Of Common Stock Initial Public Offering IssuanceOfCommonStockInitialPublicOffering	18329000	USD
CY2017	cdna	Stock Issued During Period Value Business Acquisitions StockIssuedDuringPeriodValueBusinessAcquisitions	1146000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	1676000	USD
CY2017	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	94000	USD
CY2017	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	245000	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	262000	USD
CY2017	cdna	Issuance Of Common Stock For Cash Upon Exercise Of Warrants Value IssuanceOfCommonStockForCashUponExerciseOfWarrantsValue	989000	USD
CY2017	cdna	Issuance Of Common Stock Upon Exercise Of Warrants Value IssuanceOfCommonStockUponExerciseOfWarrantsValue	4306000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1492000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1306000	USD
CY2017	us-gaap	Profit Loss ProfitLoss	-55560000	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-5954000	USD
CY2018	cdna	Adjustments To Additional Paid In Capital Reclassification Of Warrants From Liability To Equity AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity	6550000	USD
CY2018	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3800000	USD
CY2018	cdna	Issuance Of Common Stock Initial Public Offering IssuanceOfCommonStockInitialPublicOffering	52549000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	38852000	USD
CY2018	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	287000	USD
CY2018	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-698000	USD
CY2018	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	273000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1480000	USD
CY2018	cdna	Noncontrolling Interest Increase Decrease From Business Combination NoncontrollingInterestIncreaseDecreaseFromBusinessCombination	-692000	USD
CY2018	cdna	Issuance Of Common Stock For Cash Upon Exercise Of Warrants Value IssuanceOfCommonStockForCashUponExerciseOfWarrantsValue	38712000	USD
CY2018	cdna	Stock Issued During Period Value Business Acquisitions StockIssuedDuringPeriodValueBusinessAcquisitions	2689000	USD
CY2018	cdna	Issuance Of Warrants In Connection With Perceptive Debt IssuanceOfWarrantsInConnectionWithPerceptiveDebt	784000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1933000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	-46781000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	95928000	USD
CY2019	cdna	Additional Paid In Capital Contingent Consideration Classified As Equity AdditionalPaidInCapitalContingentConsiderationClassifiedAsEquity	222000	USD
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	759000	USD
CY2019	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-4152000	USD
CY2019	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	209000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3553000	USD
CY2019	cdna	Issuance Of Common Stock For Cash Upon Exercise Of Warrants Value IssuanceOfCommonStockForCashUponExerciseOfWarrantsValue	3181000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-927000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-21968000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	99000000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-21968000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	-46781000	USD
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-160000	USD
CY2017	us-gaap	Profit Loss ProfitLoss	-55560000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	22417000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	7138000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	1744000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	0	USD
CY2018	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	234000	USD
CY2017	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	418000	USD
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2017	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-10000	USD
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5523000	USD
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4215000	USD
CY2017	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3727000	USD
CY2019	cdna	Noncash Lease Expense NoncashLeaseExpense	1621000	USD
CY2018	cdna	Noncash Lease Expense NoncashLeaseExpense	0	USD
CY2017	cdna	Noncash Lease Expense NoncashLeaseExpense	0	USD
CY2019	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	319000	USD
CY2018	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-22978000	USD
CY2017	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-29622000	USD
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	210000	USD
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1017000	USD
CY2017	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1180000	USD
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
CY2018	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2232000	USD
CY2017	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3452000	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2017	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	1958000	USD
CY2019	cdna	Loss On Conversion Of Debt To Equity LossOnConversionOfDebtToEquity	0	USD
CY2018	cdna	Loss On Conversion Of Debt To Equity LossOnConversionOfDebtToEquity	5831000	USD
CY2017	cdna	Loss On Conversion Of Debt To Equity LossOnConversionOfDebtToEquity	274000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	12675000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3967000	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	109000	USD
CY2018	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	1607000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1270000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-363000	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1025000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	829000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	502000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	84000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1351000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-168000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	292000	USD
CY2019	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	3115000	USD
CY2018	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	4291000	USD
CY2017	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	1065000	USD
CY2019	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	3029000	USD
CY2018	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	719000	USD
CY2017	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-1233000	USD
CY2019	cdna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-1854000	USD
CY2019	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	1280000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2769000	USD
CY2017	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	2088000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4007000	USD
CY2017	cdna	Payments To Acquire Capital Expenditures Net PaymentsToAcquireCapitalExpendituresNet	186000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14307000	USD
CY2019	cdna	Payments To Acquire Capital Expenditures Net PaymentsToAcquireCapitalExpendituresNet	2201000	USD
CY2018	cdna	Payments To Acquire Capital Expenditures Net PaymentsToAcquireCapitalExpendituresNet	2035000	USD
CY2019	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1148000	USD
CY2018	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	5202000	USD
CY2017	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2019	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	18230000	USD
CY2018	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	692000	USD
CY2017	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	5919000	USD
CY2019	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	1000000	USD
CY2018	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	USD
CY2017	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22579000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7929000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6105000	USD
CY2019	cdna	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	0	USD
CY2018	cdna	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	52910000	USD
CY2017	cdna	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	18328000	USD
CY2019	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0	USD
CY2018	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	14282000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3553000	USD
CY2017	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	24002000	USD
CY2019	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	172000	USD
CY2018	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	28089000	USD
CY2017	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	14359000	USD
CY2019	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	0	USD
CY2018	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-677000	USD
CY2017	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	0	USD
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	105000	USD
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	10998000	USD
CY2017	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	989000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1480000	USD
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	262000	USD
CY2019	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	760000	USD
CY2018	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	287000	USD
CY2017	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	94000	USD
CY2019	cdna	Taxes Paid Related To Net Share Settlement Of Restricted Stock Units TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits	4153000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-849000	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2000	USD
CY2017	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	106000	USD
CY2018	cdna	Taxes Paid Related To Net Share Settlement Of Restricted Stock Units TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits	698000	USD
CY2017	cdna	Taxes Paid Related To Net Share Settlement Of Restricted Stock Units TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits	0	USD
CY2019	us-gaap	Proceeds From Repayments Of Bank Overdrafts ProceedsFromRepaymentsOfBankOverdrafts	0	USD
CY2018	us-gaap	Proceeds From Repayments Of Bank Overdrafts ProceedsFromRepaymentsOfBankOverdrafts	0	USD
CY2017	us-gaap	Proceeds From Repayments Of Bank Overdrafts ProceedsFromRepaymentsOfBankOverdrafts	63000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-132000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	50268000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	29379000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-26329000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	38334000	USD
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9073000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	64808000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26474000	USD
CY2018	cdna	Common Stock Issued For Acquisition CommonStockIssuedForAcquisition	0	USD
CY2017	cdna	Common Stock Issued For Acquisition CommonStockIssuedForAcquisition	0	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17401000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38479000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	64808000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26474000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	22000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	1774000	USD
CY2017	us-gaap	Interest Paid Net InterestPaidNet	3270000	USD
CY2019	cdna	Shares Issued In Lieu Of Cash Payment SharesIssuedInLieuOfCashPayment	209000	USD
CY2018	cdna	Shares Issued In Lieu Of Cash Payment SharesIssuedInLieuOfCashPayment	0	USD
CY2017	cdna	Shares Issued In Lieu Of Cash Payment SharesIssuedInLieuOfCashPayment	1145000	USD
CY2019	cdna	Business Acquisition Deferred Payment Consideration BusinessAcquisitionDeferredPaymentConsideration	0	USD
CY2018	cdna	Business Acquisition Deferred Payment Consideration BusinessAcquisitionDeferredPaymentConsideration	0	USD
CY2017	cdna	Business Acquisition Deferred Payment Consideration BusinessAcquisitionDeferredPaymentConsideration	0	USD
CY2019	cdna	Accrued Interest Capitalized To Debt Principal AccruedInterestCapitalizedToDebtPrincipal	0	USD
CY2018	cdna	Accrued Interest Capitalized To Debt Principal AccruedInterestCapitalizedToDebtPrincipal	0	USD
CY2017	cdna	Accrued Interest Capitalized To Debt Principal AccruedInterestCapitalizedToDebtPrincipal	984000	USD
CY2019	cdna	Common Stock Issued For Acquisition CommonStockIssuedForAcquisition	7207000	USD
CY2019	cdna	Operating Leases Right Of Use Assets Of Cash Flow Information OperatingLeasesRightOfUseAssetsOfCashFlowInformation	6138000	USD
CY2018	cdna	Debt Conversion Converted Instrument Common Stock Warrants Issued DebtConversionConvertedInstrumentCommonStockWarrantsIssued	784000	USD
CY2019	cdna	Conversion Of Convertible Preferred Stock To Common Stock At Private Placement And Subsequent Financing ConversionOfConvertiblePreferredStockToCommonStockAtPrivatePlacementAndSubsequentFinancing	576000	USD
CY2018	cdna	Conversion Of Convertible Preferred Stock To Common Stock At Private Placement And Subsequent Financing ConversionOfConvertiblePreferredStockToCommonStockAtPrivatePlacementAndSubsequentFinancing	0	USD
CY2017	cdna	Conversion Of Convertible Preferred Stock To Common Stock At Private Placement And Subsequent Financing ConversionOfConvertiblePreferredStockToCommonStockAtPrivatePlacementAndSubsequentFinancing	0	USD
CY2019	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2018	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	38852000	USD
CY2017	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2019	cdna	Offering Costs OfferingCosts	0	USD
CY2018	cdna	Offering Costs OfferingCosts	361000	USD
CY2017	cdna	Offering Costs OfferingCosts	0	USD
CY2019	cdna	Employee Stock Purchase Plan Shares EmployeeStockPurchasePlanShares	703000	USD
CY2018	cdna	Employee Stock Purchase Plan Shares EmployeeStockPurchasePlanShares	341000	USD
CY2017	cdna	Employee Stock Purchase Plan Shares EmployeeStockPurchasePlanShares	0	USD
CY2019	cdna	Debt Conversion Converted Instrument Common Stock Warrants Issued DebtConversionConvertedInstrumentCommonStockWarrantsIssued	0	USD
CY2017	cdna	Debt Conversion Converted Instrument Common Stock Warrants Issued DebtConversionConvertedInstrumentCommonStockWarrantsIssued	0	USD
CY2019	cdna	Common Stock Shares Issued For Contingent Consideration CommonStockSharesIssuedForContingentConsideration	1442000	USD
CY2018	cdna	Common Stock Shares Issued For Contingent Consideration CommonStockSharesIssuedForContingentConsideration	2689000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	64808000	USD
CY2017	cdna	Common Stock Shares Issued For Contingent Consideration CommonStockSharesIssuedForContingentConsideration	0	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38223000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	64616000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16895000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	256000	USD
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	192000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	9579000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38479000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26474000	USD
CY2019	cdna	Number Of Transplant Centers NumberOfTransplantCenters	84	segment
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-333800000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38200000	USD
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Use of Estimates</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to transaction price estimates used for testing revenue; accrued expenses for clinical studies inventory valuation; the fair value of issued common stock warrants; the fair value of assets and liabilities acquired in a business combination or an assets acquisition (including identifiable intangible assets acquired); the fair value of contingent consideration recorded in connection with a business combination; the grant date fair value assumptions used to estimate stock-based compensation expense; income taxes; impairment of long-lived assets and indefinite-lived assets (including goodwill); and legal contingencies. Actual results could differ from those estimates.</span></div>
CY2019	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Concentrations of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and accounts receivable. The Company’s policy is to invest its cash and cash equivalents in money market funds, obligations of U.S. government agencies and government-sponsored entities, commercial paper and various bank deposit accounts. These financial instruments are held in Company accounts at twelve financial institutions. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">event of default by the financial institutions to the extent of amounts recorded on the balance sheets that may be in excess of insured limits.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is also subject to credit risk from its accounts receivable, which are derived from revenue earned from AlloSure Kidney and AlloMap Heart tests provided for patients located in the U.S. and billed to various third-party payers, from sales of products to distributors, strategic partners and transplant laboratories in Europe, the Middle East, Africa, the U.S., Latin America and other geographic regions, and from sales of digital solutions software. The Company has not experienced any significant credit losses and does not require collateral on receivables. For the years ended December 31, 2019, 2018 and 2017, approximately 55%, 48% and 27%, respectively, of total revenue was billed to Medicare. No other payers represented more than 10% of total revenue for the years ended December 31, 2019, 2018 and 2017.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2019 and 2018, approximately 36% and 27%, respectively, of accounts receivable was due from Medicare. No other payer represented more than 10% of accounts receivable at either December 31, 2019 or 2018.</span></div>
CY2019Q4	cdna	Number Of Financial Institutions Holding Financial Instruments NumberOfFinancialInstitutionsHoldingFinancialInstruments	12	financialInstitution
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	300000	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-21968000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-46756000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-55469000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-21968000	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-46756000	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-55469000	USD
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42151617	shares
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35638956	shares
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23332503	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42151617	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35638956	shares
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23332503	shares
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.52
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.31
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.38
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.52
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.31
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.38
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4481383	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4125710	shares
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12411471	shares
CY2017Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	34984000	USD
CY2018	cdna	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Exercise Of Warrants FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisExerciseOfWarrants	27714000	USD
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	12268000	USD
CY2018	cdna	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Reclassification To Equity FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity	6550000	USD
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	245000	USD
CY2018	cdna	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Issuances Of Common Stock FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIssuancesOfCommonStock	-2689000	USD
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	23995000	USD
CY2018Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	10003000	USD
CY2019	cdna	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Exercise Of Warrants FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisExerciseOfWarrants	3077000	USD
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-319000	USD
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	6607000	USD
CY2019Q4	cdna	Number Of Investments NumberOfInvestments	1	investment
CY2019Q2	us-gaap	Finite Lived Intangible Assets Fair Value Disclosure FiniteLivedIntangibleAssetsFairValueDisclosure	6600000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	12005000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	12005000	USD
CY2019	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	11852000	USD
CY2018	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	0	USD
CY2019Q4	us-gaap	Goodwill Goodwill	23857000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	12005000	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	57713000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7143000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	10719000	USD
CY2019Q4	cdna	Finite Lived Intangible Foreign Currency Translation FiniteLivedIntangibleForeignCurrencyTranslation	3556000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	43438000	USD
CY2019Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	59816000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	10719000	USD
CY2019Q4	cdna	Finite Lived Intangible Foreign Currency Translation FiniteLivedIntangibleForeignCurrencyTranslation	3556000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	45541000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	38255000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7143000	USD
CY2018Q4	cdna	Finite Lived Intangible Foreign Currency Translation FiniteLivedIntangibleForeignCurrencyTranslation	2682000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	28430000	USD
CY2018Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	43077000	USD
CY2018Q4	cdna	Finite Lived Intangible Foreign Currency Translation FiniteLivedIntangibleForeignCurrencyTranslation	2682000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	33252000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3600000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2400000	USD
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2600000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	4676000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	4439000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	4422000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	4422000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	4422000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	21057000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	43438000	USD
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1236000	USD
CY2018Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2506000	USD
CY2019Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1189000	USD
CY2018Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	651000	USD
CY2019Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	3589000	USD
CY2018Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1786000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	6014000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	4943000	USD
CY2019Q4	cdna	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	19523000	USD
CY2018Q4	cdna	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	18234000	USD
CY2019Q4	cdna	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	15093000	USD
CY2018Q4	cdna	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	14100000	USD
CY2019Q4	cdna	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	4430000	USD
CY2018Q4	cdna	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	4134000	USD
CY2019	us-gaap	Depreciation Depreciation	1600000	USD
CY2017	us-gaap	Depreciation Depreciation	1200000	USD
CY2018	us-gaap	Depreciation Depreciation	1200000	USD
CY2018Q4	cdna	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	600000	USD
CY2019Q4	cdna	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	600000	USD
CY2019Q4	cdna	Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization FinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	400000	USD
CY2018Q4	cdna	Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization FinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	200000	USD
CY2019	us-gaap	Adjustment For Amortization AdjustmentForAmortization	200000	USD
CY2018	us-gaap	Adjustment For Amortization AdjustmentForAmortization	200000	USD
CY2017	us-gaap	Adjustment For Amortization AdjustmentForAmortization	100000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3686000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	39000	USD
CY2019Q4	cdna	Accrued Clinical And Cost Of Other Studies Current AccruedClinicalAndCostOfOtherStudiesCurrent	3068000	USD
CY2018Q4	cdna	Accrued Clinical And Cost Of Other Studies Current AccruedClinicalAndCostOfOtherStudiesCurrent	1815000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3017000	USD
CY2019Q4	cdna	Deferred Payments For Intangible Assets DeferredPaymentsForIntangibleAssets	2098000	USD
CY2018Q4	cdna	Deferred Payments For Intangible Assets DeferredPaymentsForIntangibleAssets	0	USD
CY2019Q4	cdna	Accrued Sample Processing Fees AccruedSampleProcessingFees	835000	USD
CY2018Q4	cdna	Accrued Sample Processing Fees AccruedSampleProcessingFees	657000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	810000	USD
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	766000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	822000	USD
CY2019Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	547000	USD
CY2018Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	285000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2011000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2019000	USD
CY2019Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	16838000	USD
CY2018Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	5637000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	1993000	USD
CY2019	cdna	Finance Lease Cost FinanceLeaseCost	218000	USD
CY2019	us-gaap	Lease Cost LeaseCost	2211000	USD
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y2M15D
CY2019Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y3M21D
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.105
CY2019Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.066
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	2300000	USD
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2000000.0	USD
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1700000	USD
CY2019Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	209000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3416000	USD
CY2019Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	71000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1350000	USD
CY2019Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	0	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1258000	USD
CY2019Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	280000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	6024000	USD
CY2014Q2	cdna	Number Of Milestone Payments NumberOfMilestonePayments	6	milestone_payment
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	600000	USD
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	300000	USD
CY2019	cdna	Stock Issued During Period Shares Warrants Exercises In Period StockIssuedDuringPeriodSharesWarrantsExercisesInPeriod	94000	shares
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	100000	USD
CY2019	cdna	Number Of Warrants Exercised Cashless Basis NumberOfWarrantsExercisedCashlessBasis	207400	shares
CY2019	cdna	Stock Issued During Period Shares Cashless Warrants Exercises In Period StockIssuedDuringPeriodSharesCashlessWarrantsExercisesInPeriod	49000	shares
CY2018	cdna	Stock Issued During Period Shares Warrants Exercises In Period StockIssuedDuringPeriodSharesWarrantsExercisesInPeriod	2998000	shares
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	11000000.0	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	322178	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2501057	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.10
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	1855398	shares
CY2019	cdna	Share Based Compensation Arrangement By Share Based Payment Award Common Stock Awards For Services ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices	7569	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	991130	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	991130	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	27.88
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	625685	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.70
CY2019	cdna	Share Based Compensation Arrangement By Share Based Payment Award Repurchases Of Common Stock Under Employee Incentive Plans ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans	142103	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	187229	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	241533	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	241533	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	15.37
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	15121	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	15121	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	6.45
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	504775	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2609848	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.47
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	15100000	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	6800000	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	200000	USD
CY2019Q4	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber	1017549	shares
CY2019	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice	8.57
CY2019	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm	P6Y5M12D
CY2019Q4	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue	13795000	USD
CY2019Q4	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber	1488440	shares
CY2019Q4	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice	21.52
CY2019	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm	P8Y10M20D
CY2019Q4	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue	6055000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2505989	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	19850000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	17.74
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.05
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.60
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	4000000.0	USD
CY2019Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	17700000	USD
CY2019	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y18D
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22417000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7138000	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1744000	USD
CY2019	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
CY2019	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	0	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-571000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-19386000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-41109000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-50132000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-4561000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-7106000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-7137000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23947000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-48215000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-57269000	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	24000	USD
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	74000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1000	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-4000	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	83000	USD
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	139000	USD
CY2017	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	68000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-487000	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	163000	USD
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	138000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-558000	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	13000	USD
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	42000	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-47000	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	4000	USD
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1000	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-887000	USD
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1614000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1979000	USD
CY2017	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1890000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1492000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1597000	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1847000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1434000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1709000	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.099
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.013
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.002
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.166
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.094
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.380
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.003
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.024
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.011
CY2019	cdna	Effective Income Tax Rate Reconciliation Warrant Revaluation EffectiveIncomeTaxRateReconciliationWarrantRevaluation	0.003
CY2018	cdna	Effective Income Tax Rate Reconciliation Warrant Revaluation EffectiveIncomeTaxRateReconciliationWarrantRevaluation	-0.100
CY2017	cdna	Effective Income Tax Rate Reconciliation Warrant Revaluation EffectiveIncomeTaxRateReconciliationWarrantRevaluation	-0.175
CY2019	cdna	Effective Income Tax Rate Reconciliation Interest Expense EffectiveIncomeTaxRateReconciliationInterestExpense	-0.002
CY2018	cdna	Effective Income Tax Rate Reconciliation Interest Expense EffectiveIncomeTaxRateReconciliationInterestExpense	-0.017
CY2017	cdna	Effective Income Tax Rate Reconciliation Interest Expense EffectiveIncomeTaxRateReconciliationInterestExpense	-0.018
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	0
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	-0.012
CY2019	cdna	Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit Percent TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefitPercent	0
CY2018	cdna	Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit Percent TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefitPercent	0
CY2017	cdna	Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit Percent TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefitPercent	-0.465
CY2019	cdna	Effective Income Tax Rate Reconciliation Nondeductible Expense Executive Share Based Compensation Cost Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveShareBasedCompensationCostPercent	-0.076
CY2018	cdna	Effective Income Tax Rate Reconciliation Nondeductible Expense Executive Share Based Compensation Cost Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveShareBasedCompensationCostPercent	-0.007
CY2017	cdna	Effective Income Tax Rate Reconciliation Nondeductible Expense Executive Share Based Compensation Cost Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveShareBasedCompensationCostPercent	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.012
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.007
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.083
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.030
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.030
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	56735000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	52135000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	7239000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	6235000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	2649000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	3068000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1078000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1571000	USD
CY2019Q4	cdna	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	1015000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2224000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	812000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	70940000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	63821000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	64412000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	60327000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	6528000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3494000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	7589000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	6429000	USD
CY2019Q4	cdna	Deferred Tax Liabilities Operating Leases Right Of Use Assets DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets	878000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	34000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	33000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	8501000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	6462000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1973000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2968000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3164000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	100000	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4100000	USD
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-5400000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3449000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3164000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5252000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	667000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	285000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	186000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	466000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2017	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	2274000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3650000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3449000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3700000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	200000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	300000	USD
CY2016	cdna	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Deferred Tax Assets TaxCutsAndJobsActOf2017IncompleteAccountingDeferredTaxAssets	72500000	USD
CY2017Q4	cdna	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Deferred Tax Assets TaxCutsAndJobsActOf2017IncompleteAccountingDeferredTaxAssets	45900000	USD
CY2017Q4	cdna	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Decrease In Valuation Allowance TaxCutsAndJobsActOf2017IncompleteAccountingDecreaseInValuationAllowance	27000000.0	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	127068000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	76569000	USD
CY2017	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48324000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4430000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4134000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25982000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31454000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	33811000	USD
CY2019Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	35821000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-7531000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-7847000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-1813000	USD
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-4777000	USD
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2019Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2019Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2019Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2019Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42393550	shares
CY2019Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42457171	shares
CY2019Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41611399	shares
CY2019Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42132396	shares
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42393550	shares
CY2019Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42457171	shares
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41611399	shares
CY2019Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42132396	shares
CY2018Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14053000	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	17823000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21184000	USD
CY2018Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	23509000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-8969000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-14062000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-19970000	USD
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-3755000	USD
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
CY2018Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
CY2018Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.54
CY2018Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30
CY2018Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.40
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.54
CY2018Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2018Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29615441	shares
CY2018Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35549837	shares
CY2018Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37154293	shares
CY2018Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40104341	shares
CY2018Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29615441	shares
CY2018Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35549837	shares
CY2018Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37154293	shares
CY2018Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40104341	shares

Files In Submission

Name	View Source	Status
0001217234-20-000033-index-headers.html	Edgar Link	pending
0001217234-20-000033-index.html	Edgar Link	pending
0001217234-20-000033.txt	Edgar Link	pending
0001217234-20-000033-xbrl.zip	Edgar Link	pending
cdna-20191231.htm	Edgar Link	pending
cdna-20191231.xsd	Edgar Link	pending
cdna-20191231x10kxexx3.htm	Edgar Link	pending
cdna-20191231x10kxexx31.htm	Edgar Link	pending
cdna-20191231x10kxexx32.htm	Edgar Link	pending
cdna-20191231x10kxexx49.htm	Edgar Link	pending
cdna-20191231_cal.xml	Edgar Link	unprocessable
cdna-20191231_def.xml	Edgar Link	unprocessable
cdna-20191231_g1.jpg	Edgar Link	pending
cdna-20191231_htm.xml	Edgar Link	completed
cdna-20191231_lab.xml	Edgar Link	unprocessable
cdna-20191231_pre.xml	Edgar Link	unprocessable
exhibit1010outsidedire.htm	Edgar Link	pending
exhibit211-listofsubs.htm	Edgar Link	pending
exhibit231-deloittecon.htm	Edgar Link	pending
exhibit232-eyconsent.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CDNA
CareDx, Inc. Stock $cdna

2019 Q4 Form 10-K Financial Statement

#000121723420000033 Filed on February 28, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDNA CareDx, Inc. Stock $cdna

2019 Q4 Form 10-K Financial Statement

#000121723420000033 Filed on February 28, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDNA
CareDx, Inc. Stock $cdna